Several therapeutic options are available for pretreated patients with hormone therapy or chemotherapy (docetaxel): cabazitaxel, olaparib, and rucaparib for PC patients with BRCA mutations, Radium-223 for specific patients who have symptomatic bone metastasis, the first approved vaccine for PC patients sipuleucel-T, and 177LuPSMA-617 (radiopharmaceutical directed to prostate-specific membrane antigen-presenting cells). This evidence concerns the gene FOLH1 and pachyonychia congenita.